U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
9882198821Cat-PAD Follow on StudyCompletedNo Results AvailableCat Allergy|RhinoconjunctivitisBiological: Placebo|Biological: Cat-PAD Dose 1|Biological: Cat-PAD Dose 2https://ClinicalTrials.gov/show/NCT01272323
9882298822Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon Alpha-2a and Ribavirin in Chronic Hepatitis C Subjects Non-responders to the Standard of Care Therapy.Not yet recruitingNo Results AvailableChronic Hepatitis CBiological: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirinhttps://ClinicalTrials.gov/show/NCT01272310
9882398823The Effect of Low Intensity Shock Wave Therapy for ED in PDE5i Non RespondersCompletedNo Results AvailableErectile DysfunctionDevice: LI-ESWThttps://ClinicalTrials.gov/show/NCT01272297
9882498824The Altis® Single Incision Sling System for Female Stress Urinary Incontinence StudyCompletedHas ResultsStress Urinary IncontinenceDevice: Altis® Single Incision Sling System (SIS)https://ClinicalTrials.gov/show/NCT01272284
9882598825Safety of Overnight Corneal Reshaping LensesCompletedNo Results AvailableKeratitis|Myopiahttps://ClinicalTrials.gov/show/NCT01272271
9882698826A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor AdherenceNot yet recruitingNo Results AvailableHIVDrug: PRO 140|Drug: Placebohttps://ClinicalTrials.gov/show/NCT01272258
9882798827Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)Active, not recruitingNo Results AvailableLeukemiaDrug: Omacetaxine|Drug: Cytarabinehttps://ClinicalTrials.gov/show/NCT01272245
9882898828Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALEâ„¢ - DiabetesCompletedHas ResultsMetabolism and Nutrition Disorder|ObesityDrug: liraglutide|Drug: liraglutide|Drug: placebohttps://ClinicalTrials.gov/show/NCT01272232
9882998829Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALEâ„¢ - Obesity and Pre-diabetesCompletedHas ResultsMetabolism and Nutrition Disorder|ObesityDrug: liraglutide|Drug: placebo|Drug: placebo|Drug: liraglutide|Drug: placebohttps://ClinicalTrials.gov/show/NCT01272219
9883098830Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male SubjectsCompletedNo Results AvailableCongenital Bleeding Disorder|Haemophilia A|Haemophilia BDrug: NNC 0128-0000-2011|Drug: NNC 0128-0000-2021https://ClinicalTrials.gov/show/NCT01272206
9883198831Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjets With Type 2 DiabetesCompletedNo Results AvailableDiabetes|Diabetes Mellitus, Type 2Drug: insulin degludec/insulin aspart|Drug: insulin glarginehttps://ClinicalTrials.gov/show/NCT01272193
9883298832Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young AdultsCompletedHas ResultsInvasive Meningococcal DiseaseBiological: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.|Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.|Biological: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.|Biological: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.https://ClinicalTrials.gov/show/NCT01272180
9883398833Effects of a Long-term Grapefruit Juice Consumption on Vascular Protection and Bone MetabolismCompletedNo Results AvailablePost-menopausal StatusBehavioral: Long-term grapefruit juice consumptionhttps://ClinicalTrials.gov/show/NCT01272167
9883498834Cerebellum and Cortical Plasticity: the Case of DystoniaRecruitingNo Results AvailableDystoniaOther: Transcranial magnetic stimulationhttps://ClinicalTrials.gov/show/NCT01272154
9883598835A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast CancerTerminatedHas ResultsBreast Neoplasms|Breast Cancer|Cancer of the BreastDrug: Lapatinib and Everolimushttps://ClinicalTrials.gov/show/NCT01272141
9883698836Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL StudyActive, not recruitingNo Results AvailableMultiple SclerosisDrug: Interferon beta-1ahttps://ClinicalTrials.gov/show/NCT01272128
9883798837Integrative Health Care Model for Climacteric Stage WomenCompletedNo Results AvailableState; ClimactericBehavioral: Integrative health care modelhttps://ClinicalTrials.gov/show/NCT01272115
9883898838Macular Ganglion Cell Analysis (GCA) of the Cirrus HD-OCT in GlaucomaCompletedNo Results AvailableGlaucomahttps://ClinicalTrials.gov/show/NCT01272102
9883998839A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic ConjunctivitisCompletedNo Results AvailableAllergic ConjunctivitisDrug: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%https://ClinicalTrials.gov/show/NCT01272089
9884098840Cirrus HD-OCT Measurement of Area of Increased Light Penetration Under the Retinal Pigment Epithelium (RPE)CompletedHas ResultsAge Related Macular Degeneration|Geographic Atrophyhttps://ClinicalTrials.gov/show/NCT01272076
9884198841Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus PhotographyCompletedNo Results AvailableDrusen Stage Macular Degenerationhttps://ClinicalTrials.gov/show/NCT01272063
9884298842Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After SurgeryActive, not recruitingNo Results AvailableProstate CancerRadiation: radiation therapyhttps://ClinicalTrials.gov/show/NCT01272050
9884398843Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast CancerRecruitingNo Results AvailableDuctal Breast Carcinoma In Situ|Estrogen Receptor and/or Progesterone Receptor Positive|HER2/Neu Negative|Invasive Breast Carcinoma|Multicentric Breast Carcinoma|Multifocal Breast Carcinoma|Synchronous Bilateral Breast CarcinomaDrug: Anastrozole|Drug: Exemestane|Other: Laboratory Biomarker Analysis|Drug: Letrozole|Other: Quality-of-Life Assessment|Drug: Systemic Chemotherapy|Drug: Tamoxifen Citratehttps://ClinicalTrials.gov/show/NCT01272037
9884498844An Intervention to Improve Outcomes in Patients With Advanced CancerRecruitingNo Results AvailableCancerBehavioral: Symptom Education|Behavioral: Interventionhttps://ClinicalTrials.gov/show/NCT01272024
9884598845Effects of Breathing and Walking Treatments on Recovery Post-Spinal Cord InjuryCompletedNo Results AvailableSpinal Cord Injuries|Brown Sequard|Central Cord SyndromeOther: Breathing (Hypoxia) Treatment|Other: Breathing (Hypoxia) Treatment and Locomotor Traininghttps://ClinicalTrials.gov/show/NCT01272011
9884698846Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mgCompletedNo Results AvailableBacterial InfectionDrug: TR-701 FAhttps://ClinicalTrials.gov/show/NCT01271998
9884798847Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPillActive, not recruitingNo Results AvailableCardiovascular DiseasesDrug: PolyPill|Other: Minimal carehttps://ClinicalTrials.gov/show/NCT01271985
9884898848Study of Nesvacumab (REGN910/ SAR307746)CompletedNo Results AvailableSolid TumorsDrug: nesvacumab (REGN910/ SAR307746)https://ClinicalTrials.gov/show/NCT01271972
9884998849A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry StudyTerminatedNo Results AvailableSolid Organ Tumorshttps://ClinicalTrials.gov/show/NCT01271959
9885098850A Patient Registry Evaluating Closure Following Access With the ArstasisOne Access SystemCompletedHas ResultsDiagnostic Catheterization Access Through a 5F or 6F Femoral Artery IntroducerDevice: Diagnostic catheterization procedurehttps://ClinicalTrials.gov/show/NCT01271946

* Görseller ve İçerik tekif hakkına sahip olabilir